INDEX.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:29):

Stats
Dzisiejszy wolumen	4.43M
Średni wolumen	2.23M
Kapitalizacja rynkowa	196.03M
EPS	SEK0 ( 2024-02-20 )
Następna data zysków	( SEK0 ) 2024-05-21
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.04
ATR14	SEK0.00200 (0.54%)

Wolumen Korelacja

Długi: 0.01 (neutral)

Krótki: 0.61 (weak)

Signal:(52.23) Neutral

InDex Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

InDex Pharmaceuticals Korelacja - Waluta/Towar

0.08
( neutral )

0.23
( neutral )

0.00
( neutral )

-0.19
( neutral )

InDex Pharmaceuticals Finanse

Annual	2023
Przychody:	SEK97.51M
Zysk brutto:	SEK-95.71M (-98.16 %)
EPS:	SEK-0.180

FY	2023
Przychody:	SEK97.51M
Zysk brutto:	SEK-95.71M (-98.16 %)
EPS:	SEK-0.180

FY	2023
Przychody:	SEK0
Zysk brutto:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
Przychody:	SEK1.15M
Zysk brutto:	SEK-9.14M (-797.64 %)
EPS:	SEK-0.180

Financial Reports:

No articles found.

InDex Pharmaceuticals

InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.